LSE:MDC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Mediclinic International

Executive Summary

Mediclinic International plc, together with its subsidiaries, operates private hospitals. More Details


Snowflake Analysis

Fair value with moderate growth potential.


Similar Companies

Share Price & News

How has Mediclinic International's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MDC has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

8.2%

MDC

3.4%

GB Healthcare

0.07%

GB Market


1 Year Return

-17.6%

MDC

-4.2%

GB Healthcare

-15.4%

GB Market

Return vs Industry: MDC underperformed the UK Healthcare industry which returned -4.2% over the past year.

Return vs Market: MDC underperformed the UK Market which returned -15.4% over the past year.


Shareholder returns

MDCIndustryMarket
7 Day8.2%3.4%0.07%
30 Day15.7%5.5%1.7%
90 Day7.3%7.9%-1.8%
1 Year-16.9%-17.6%-2.6%-4.2%-12.1%-15.4%
3 Year-45.5%-48.0%-32.4%-35.9%-8.4%-19.7%
5 Yearn/a11.3%1.3%16.4%-9.7%

Price Volatility Vs. Market

How volatile is Mediclinic International's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Mediclinic International undervalued compared to its fair value and its price relative to the market?

32.1%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MDC (£3.07) is trading below our estimate of fair value (£4.53)

Significantly Below Fair Value: MDC is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MDC is unprofitable, so we can't compare its PE Ratio to the GB Healthcare industry average.

PE vs Market: MDC is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MDC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MDC is good value based on its PB Ratio (0.8x) compared to the GB Healthcare industry average (1.4x).


Next Steps

Future Growth

How is Mediclinic International forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

62.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MDC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).

Earnings vs Market: MDC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MDC's is expected to become profitable in the next 3 years.

Revenue vs Market: MDC's revenue (2.9% per year) is forecast to grow slower than the UK market (6% per year).

High Growth Revenue: MDC's revenue (2.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MDC's Return on Equity is forecast to be low in 3 years time (6.4%).


Next Steps

Past Performance

How has Mediclinic International performed over the past 5 years?

-49.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MDC is currently unprofitable.

Growing Profit Margin: MDC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MDC is unprofitable, and losses have increased over the past 5 years at a rate of 49.9% per year.

Accelerating Growth: Unable to compare MDC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MDC is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-1.2%).


Return on Equity

High ROE: MDC has a negative Return on Equity (-9.96%), as it is currently unprofitable.


Next Steps

Financial Health

How is Mediclinic International's financial position?


Financial Position Analysis

Short Term Liabilities: MDC's short term assets (£1.2B) exceed its short term liabilities (£769.0M).

Long Term Liabilities: MDC's short term assets (£1.2B) do not cover its long term liabilities (£3.2B).


Debt to Equity History and Analysis

Debt Level: MDC's debt to equity ratio (65.3%) is considered high.

Reducing Debt: MDC's debt to equity ratio has reduced from 88.7% to 65.3% over the past 5 years.

Debt Coverage: MDC's debt is well covered by operating cash flow (23.3%).

Interest Coverage: MDC is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet


Next Steps

Dividend

What is Mediclinic International current dividend yield, its reliability and sustainability?

1.69%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MDC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MDC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MDC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MDC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: MDC is not paying a notable dividend for the UK market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MDC's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.2yrs

Average management tenure


CEO

Ronnie van der Merwe (57 yo)

2.33yrs

Tenure

UK£601,000

Compensation

Dr. Carel Aron van der Merwe, also known as Ronnie, has been Executive Director of Mediclinic International plc since June 1, 2018. Dr. van der Merwe is Group Chief Executive Officer of Mediclinic Internat ...


CEO Compensation Analysis

Compensation vs Market: Ronnie's total compensation ($USD784.11K) is below average for companies of similar size in the UK market ($USD2.08M).

Compensation vs Earnings: Ronnie's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Carel van der Merwe
Group CEO & Executive Director2.33yrsUK£601.00k0.0070%
£ 158.6k
Petrus Myburgh
Group CFO & Executive Director4.17yrsUK£442.00k0.012%
£ 278.3k
Dirk Le Roux
Group Chief Information Officer6.17yrsUK£2.40mno data
James Arnold
Head of Investor Relationsno datano datano data
Magnus Oetiker
Group Chief Human Resources & Corporate Development Officer2.67yrsno datano data
Gert Hattingh
Group Chief Corporate Services Officer4.67yrsUK£4.32m0.014%
£ 307.3k
Biren Valodia
Chief Marketing Officer of Medi-Clinic Southern Africa no datano datano data
Clara Findlay
Chief Legal Officer of Medicalinic Southern Africano datano datano data
Wimpie Aucamp
Chief Operating Officer of Medi-Clinic for Southern Africano datano datano data
Greg Wyk
Chief Human Resources Officer of Medicalinic Southern Africano datano datano data
Raymond Plotz
Chief Information Officer of Medicalinic Southern Africano datano datano data
Christian H. Westerhoff
Chief Clinical Officer of Hirslandenno datano datano data

4.2yrs

Average Tenure

54yo

Average Age

Experienced Management: MDC's management team is considered experienced (4.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Carel van der Merwe
Group CEO & Executive Director2.33yrsUK£601.00k0.0070%
£ 158.6k
Petrus Myburgh
Group CFO & Executive Director4.17yrsUK£442.00k0.012%
£ 278.3k
J. Grieve
Senior Independent Director1.25yrsUK£107.00k0.0010%
£ 23.1k
Thomas Singer
Independent Non-Executive Director1.25yrsUK£54.00kno data
Daniel Meintjes
Non-Executive Director24.75yrsUK£76.00k0.019%
£ 436.7k
Jan Durand
Non-Executive Director8.75yrsUK£83.00kno data
Muhadditha Al-Hashimi
Independent Non-Executive Director2.92yrsUK£73.00kno data
Trevor Petersen
Independent Non-Executive Director8.75yrsUK£103.00kno data
Felicity A. Harvey
Independent Non-Executive Director3yrsUK£80.00kno data
Steve Weiner
Independent Non-Executive Director0.25yrno datano data
Anja Oswald
Independent Non-Executive Director2.25yrsUK£84.00kno data
Dame Beale
Independent Non- Executive Chairman0.25yrUK£1.00kno data

2.6yrs

Average Tenure

57yo

Average Age

Experienced Board: MDC's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Mediclinic International plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Mediclinic International plc
  • Ticker: MDC
  • Exchange: LSE
  • Founded: 1983
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: UK£2.266b
  • Shares outstanding: 737.24m
  • Website: https://www.mediclinic.com

Number of Employees


Location

  • Mediclinic International plc
  • 25 Du Toit Street
  • Stellenbosch
  • Western Cape
  • 7600
  • South Africa

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MDCLSE (London Stock Exchange)YesOrdinary SharesGBGBPFeb 2016
MO4DB (Deutsche Boerse AG)YesOrdinary SharesDEEURFeb 2016
MDCLBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBGBPFeb 2016
MEIJSE (The Johannesburg Securities Exchange)YesOrdinary SharesZAZARFeb 2016
MEPNMSE (Namibian Stock Exchange)YesOrdinary SharesNAZARFeb 2016

Biography

Mediclinic International plc, together with its subsidiaries, operates private hospitals. The company offers acute care, specialist-orientated, and multidisciplinary healthcare services under the Mediclini ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/25 21:02
End of Day Share Price2020/10/23 00:00
Earnings2020/03/31
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.